In this regard, Pan et al. made significant progress with the development of the ExoSCOPE platform, which enables real-time monitoring of drug-target interactions—specifically, the EGFR inhibitor afatinib—in cancer patients using blood samples (Pan et al., 2021). Here, EGFR is linked to cancer.